Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia

Bone Marrow Transplantation

Volumn 31, Issue 12, 2003, Pages 1119-1125

  Maki, G ^a   Tam, Y K ^a   Berkahn, L ^a   Klingemann, H G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autologous stem cell transplantation; CML; Ex vivo purge; NK cells

Indexed keywords

BCR ABL PROTEIN; GUANOSINE PHOSPHATE;

ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER CELL CULTURE; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; EFFECTOR CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKAPHERESIS; NATURAL KILLER CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEM CELL; STEM CELL MOBILIZATION;

ANTIGENS, CD34; BASE SEQUENCE; BONE MARROW PURGING; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DNA, NEOPLASM; GENES, ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LEUKAPHERESIS; LEUKEMIA, MYELOID, CHRONIC; TRANSPLANTATION, AUTOLOGOUS; TUMOR STEM CELL ASSAY;

EID: 0038103033     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704117     Document Type: Article

References (38)

1. Jones RJ, Bedi A. Biology of chronic myeloid leukemia and its relevance to autologous bone marrow transplantation. Curr Opin Oncol 1994; 6: 122-126.
2. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
3. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
4. Enright H, McGlave P. Bone marrow transplantation for chronic myelogenous leukemia. Curr Opinion Oncol 1998; 10: 100-107.
5. Coulombel L, Kalousek DK, Eaves CJ et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493-1498.
6. Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
7. Petzer AL, Eaves CJ, Lansdorp PM et al. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996; 88: 2162-2171.
8. Carella AM, Podesta M, Frassoni F et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267-271.
9. Carella AM, Lerma E, Corsetti MT et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534-1539.
10. Chalmers EA, Franklin IM, Kelsey SM et al. Treatment of chronic myeloid leukemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 1997; 96: 627-634.
11. Carella AM, Cunningham I, Lerma E et al. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 1575-1582.
12. Bhatia R, Verfaillie CM, Miller JS, McGlave PB. Autologous transplantation therapy for chronic myelogenous leukemia. Blood 1997; 89: 2623-2634.
13. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001; 29: 543-556.
14. Gale RP, Horowitz MM, Ash RC et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646-652.
15. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
16. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
17. Roger R, Issaad C, Pallardy M et al. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 1996; 87: 1113-1122.
18. Cervantes F, Pierson BA, McGlave PB et al. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996; 87: 2476-2485.
19. Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 75: 2250-2262.
20. Trinchieri G. Biology of natural killer cells. Adv Immunol 1985; 47: 187-376.
21. Chiorean EG, Miller JS. The biology of natural killer cells and implications for therapy of human disease. J Hematother Stem Cell Res 2001; 10: 451-463.
22. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-658.
23. Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 1996; 87: 4913-4914.
24. Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996; 2: 68-75.
25. Yan Y, Steinherz P, Klingemann HG et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998; 4: 2859-2868.
26. Tam YK, Miyagawa B, Ho VC, Klingemann HG. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8: 281-290.
27. Maki G, Klingemann HG, Martinson JA, Tam Y. Factors regulating the cytotoxic activity of the human natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 369-383.
28. Wong EK, Eaves C, Klingemann HG. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Bone Marrow Transplant 1996; 18: 63-71.
29. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 1990; 76: 401-408.
30. Pierson BA, Miller JS. CD56 + bright and CD56 + dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88: 2279-2287.
31. Berkahn L, Simpson D, Raptis A, Klingemann HG. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J Hematother Stem Cell Res 2002; 11: 315-320.
32. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the AN tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
33. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
34. Gambacorti-Passerini C, Barni R, Marchesi E et al. Sensitivity to the abl inhibitor ST1571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol 2001; 112: 972-974.
35. Barthe C, Cony-Makhoul P, Melo JV et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163.
36. Tonn T, Becker S, Esser R et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535-544.
37. Tam YK, Maki G, Miyagawa B et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999; 10: 1359-1373.
38. Uherek C, Tonn T, Uherek B et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002; 100: 1265-1273.